2.71
price down icon2.52%   -0.07
 
loading
Inmune Bio Inc stock is traded at $2.71, with a volume of 1.02M. It is down -2.52% in the last 24 hours and down -63.23% over the past month. INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$2.78
Open:
$2.77
24h Volume:
1.02M
Relative Volume:
0.42
Market Cap:
$63.92M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-1.6228
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
+11.98%
1M Performance:
-63.23%
6M Performance:
-67.97%
1Y Performance:
-68.00%
1-Day Range:
Value
$2.615
$2.83
1-Week Range:
Value
$2.27
$3.00
52-Week Range:
Value
$1.89
$11.64

Inmune Bio Inc Stock (INMB) Company Profile

Name
Name
Inmune Bio Inc
Name
Phone
(858) 964-3720
Name
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Name
Employee
13
Name
Twitter
@INmuneBio
Name
Next Earnings Date
2025-05-02
Name
Latest SEC Filings
Name
INMB's Discussions on Twitter

Compare INMB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
INMB
Inmune Bio Inc
2.71 75.73M 155.00K -30.01M -11.98M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-01-25 Downgrade BTIG Research Buy → Neutral
Jul-01-25 Downgrade Scotiabank Sector Outperform → Sector Underperform
Jan-28-25 Initiated Rodman & Renshaw Buy
Oct-21-24 Initiated Alliance Global Partners Buy
Sep-27-24 Initiated Raymond James Outperform
Aug-22-24 Initiated Scotiabank Sector Outperform
Jun-01-23 Initiated Robert W. Baird Outperform
May-24-22 Downgrade B. Riley Securities Buy → Neutral
Jul-07-21 Reiterated Maxim Group Buy
Apr-21-21 Initiated B. Riley Securities Buy
Jan-22-21 Reiterated Maxim Group Buy
Sep-01-20 Initiated BTIG Research Buy
Jul-15-20 Reiterated H.C. Wainwright Buy
View All

Inmune Bio Inc Stock (INMB) Latest News

pulisher
05:09 AM

How does INmune Bio Inc. generate profit in a changing economyDynamic growth stocks - jammulinksnews.com

05:09 AM
pulisher
Jul 26, 2025

Why INmune Bio Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

Inmune Bio Reveals Promising XPro™ Trial Results - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about INmune Bio Inc. stockConsistently high returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is INmune Bio Inc. a good long term investmentOutstanding capital growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at - GuruFocus

Jul 25, 2025
pulisher
Jul 24, 2025

INmune Bio Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference - The Manila Times

Jul 24, 2025
pulisher
Jul 24, 2025

INmune Bio to present additional Phase 2 Alzheimer’s trial data By Investing.com - Investing.com Canada

Jul 24, 2025
pulisher
Jul 23, 2025

Is INMB more suitable for short-term or long-term investment? - AInvest

Jul 23, 2025
pulisher
Jul 22, 2025

When (INMB) Moves Investors should Listen - news.stocktradersdaily.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives INmune Bio Inc. stock priceRapid wealth accumulation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

Is INmune Bio Inc. stock overhyped or has real potentialFree Stock Selection with 300% Return - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

What makes INmune Bio Inc. stock price move sharplyFree Investment Group - beatles.ru

Jul 18, 2025
pulisher
Jul 15, 2025

How INmune Bio Inc. stock performs during market volatilityCapital Growth Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Cambridge Investment Research Advisors Inc. Makes New $180,000 Investment in INmune Bio, Inc. (NASDAQ:INMB) - Defense World

Jul 15, 2025
pulisher
Jul 12, 2025

INmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug Trial - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

Where are the Opportunities in (INMB) - news.stocktradersdaily.com

Jul 12, 2025
pulisher
Jul 07, 2025

INmune Bio shares slide after Phase II Alzheimer’s trial misses endpoints - MSN

Jul 07, 2025
pulisher
Jul 06, 2025

INmune Bio reverses early gains after stock offering - MSN

Jul 06, 2025
pulisher
Jul 06, 2025

INmune Bio surges ahead of mid-stage trial readout for Alzheimer’s drug - MSN

Jul 06, 2025
pulisher
Jul 05, 2025

INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low - MSN

Jul 05, 2025
pulisher
Jul 04, 2025

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Benzinga

Jul 04, 2025
pulisher
Jul 03, 2025

INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

INmune Bio - The Pharma Letter

Jul 03, 2025
pulisher
Jul 02, 2025

XPro™'s Subgroup Success: A Silver Lining in INmune Bio's Alzheimer's Setback - AInvest

Jul 02, 2025
pulisher
Jul 02, 2025

INmune Bio's $19M Funding: A Lifeline or a Launchpad for Breakthroughs? - AInvest

Jul 02, 2025
pulisher
Jul 01, 2025

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN

Jul 01, 2025
pulisher
Jul 01, 2025

(INMB) Proactive Strategies - news.stocktradersdaily.com

Jul 01, 2025
pulisher
Jul 01, 2025

INmune Bio Shares Fall After Downgrade From BTIG Research - MarketScreener

Jul 01, 2025
pulisher
Jul 01, 2025

INmune Bio Shares Plunge After Alzheimer's Trial Misses Target - Finimize

Jul 01, 2025
pulisher
Jul 01, 2025

INmune Bio (INMB) Faces Significant Downgrade by Scotiabank | INMB Stock News - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

A Drug-Trial Stock Sale - Bloomberg

Jul 01, 2025
pulisher
Jun 30, 2025

INmune Bio stock downgraded by Raymond James after Alzheimer’s trial miss - Investing.com Australia

Jun 30, 2025

Inmune Bio Inc Stock (INMB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Inmune Bio Inc Stock (INMB) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Tesi Raymond Joseph
President and CEO
Sep 12 '24
Buy
6.38
15,380
98,048
1,554,106
Moss David J
Chief Financial Officer
Sep 12 '24
Buy
6.38
7,690
49,024
1,275,869
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):